Goldman Sachs’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Goldman Sachs’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$384K	Buy	58,058 +4,978	+9%	+$34.3K	﹤0.01%	5861
2026 Q1	$384K	Sell	53,080 -4,978	-9%	-$40.1K	﹤0.01%	5758
2025 Q4	$438K	Buy	58,058 +17,958	+45%	+$111K	﹤0.01%	5674
2025 Q3	$237K	Buy	40,100 +300	+0.8%	+$1.63K	﹤0.01%	5883
2025 Q2	$229K	Buy	39,800 +5,300	+15%	+$20.4K	﹤0.01%	5591
2025 Q1	$113K	Hold	34,500	–	–	﹤0.01%	5763
2024 Q4	$109K	Hold	34,500	–	–	﹤0.01%	5754
2024 Q3	$90.7K	Buy	+34,500	New	+$90.7K	﹤0.01%	5579

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Goldman Sachs's EPRX Position: Q2 2026 in Review

Goldman Sachs increased its Eupraxia Pharmaceuticals (EPRX) stake by 9.4% in Q2 2026, buying an estimated $34.3K and bringing the position to 58,058 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #5861.

Goldman Sachs first reported a position in EPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $438K in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Goldman Sachs held 58,058 shares of Eupraxia Pharmaceuticals worth $384K as of Q2 2026.
Goldman Sachs bought 4,978 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $34.3K.
Eupraxia Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5861 holding.
Goldman Sachs first reported a position in Eupraxia Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Goldman Sachs's Eupraxia Pharmaceuticals position peaked at $438K in Q4 2025.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.